Yuyao Biotech

About Yuyao Biotech

Based in Shanghai, China, Yuyao Biotech, legally registered as Shanghai Yuyao Biotechnology Co., Ltd., is a biopharmaceutical company established on April 13, 2020. The firm is focused on the discovery and development of new drugs to address major clinical unmet needs, particularly in the fields of oncology, neurodegenerative diseases, and autoimmune disorders. Yuyao Biotech utilizes artificial intelligence and modern drug creation technologies to advance its pipeline of small molecule drug candidates.

The company's operational scope includes technology services, consulting, and technology transfers within the pharmaceutical space. This indicates a business model that may involve both internal asset development and providing expertise to partners. Yuyao Biotech actively forms cooperative relationships with domestic institutions and research organizations, fostering an integrated approach to production, education, and research. This strategy streamlines the path from discovery to clinical application. As a private entity, the company has successfully attracted significant investment to fuel its research and development efforts, having raised a total of $90.3 million. Key investors include Qiming Venture Partners, Shanghai Highpower Industrial, and Ling Cheng Ventures.

Yuyao Biotech's drug pipeline includes several compounds in various stages of development. Notable assets include YY-001, an EP4 antagonist for conditions like colonic cancer which has reached Phase 2, and YY-201, a STAT3 inhibitor. Recently, the company has identified new STAT3 inhibitors reported to be useful for the treatment of cancer. This focus on specific targets like STAT3 and EP4 demonstrates a targeted approach to tackling complex diseases. The business generates revenue through its development pipeline and by leveraging its AI-driven discovery platform in collaborations and service agreements.